Also trades as: OPHLY (OTC) · $vol 0M · OPHLF (OTC) · $vol 0M

¥2,278.50 ($14.43)

-11.50 (-0.50%)

Weekly Expected Move ±2.9%

¥2157 ¥2224 ¥2290 ¥2356 ¥2423

JPX · Healthcare · Drug Manufacturers - General · Tech Score Strong Sell · Power 34 · ¥1.08T mcap · 333M float · 0.481% daily turnover

Revenue

$515.8B +5.9% ▲

5Y CAGR: +10.8%

Gross Profit

$374.1B +11.5% ▲

5Y CAGR: +10.8%

Operating Income

$103.3B +63.0% ▲

5Y CAGR: +2.3%

Net Income

$69.8B +39.4% ▲

5Y CAGR: -1.5%

EPS (Diluted)

$148.42 +39.5% ▲

5Y CAGR: -0.4%

EBITDA

$133.9B +52.5% ▲

5Y CAGR: +2.8%

View Full Income Statement

Line Item	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$361.4B	$447.2B	$502.7B	$486.9B	$515.8B
YoY Growth	+16.8%	+23.8%	+12.4%	-3.1%	+5.9%
Cost of Revenue	$93.5B	$110.1B	$127.1B	$151.4B	$141.7B
Gross Profit	$267.9B	$337.1B	$375.5B	$335.5B	$374.1B
Gross Margin	74.1%	75.4%	74.7%	68.9%	72.5%
R&D Expenses	$75.9B	$95.3B	$112.4B	$149.9B	$147.0B
SG&A Expenses	$74.1B	$86.6B	$97.4B	$122.2B	$123.7B
Operating Expenses	$152.9B	$195.2B	$212.4B	$272.1B	$270.7B
Operating Income	$114.9B	$142.0B	$163.1B	$63.4B	$103.3B
Operating Margin	31.8%	31.7%	32.4%	13.0%	20.0%
Interest Expense	$874M	$913M	$229M	$1.6B	$3.5B
Income Before Tax	$105.0B	$143.5B	$163.7B	$59.3B	$92.7B
Tax Expense	$24.3B	$30.6B	$35.7B	$9.2B	$22.7B
Net Income	$80.5B	$112.7B	$128.0B	$50.0B	$69.8B
Net Margin	22.3%	25.2%	25.5%	10.3%	13.5%
EPS (Diluted)	$162.16	$230.79	$266.60	$106.41	$148.42
EBITDA	$122.8B	$161.9B	$182.1B	$90.3B	$133.9B
Shares Outstanding	1.49B	1.47B	480M	470M	470M

Line Item	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2	FY2026 Q3	FY2026 Q4
Revenue	$117.7B	$122.7B	$134.2B	$112.3B	$127.5B	$129.6B	$139.9B	$118.7B
Cost of Revenue	$29.7B	$27.2B	$45.8B	$45.2B	$37.0B	$35.0B	$36.7B	$33.1B
Gross Profit	$88.0B	$95.5B	$88.4B	$67.1B	$90.5B	$94.6B	$103.2B	$85.7B
Gross Margin	74.8%	77.8%	65.9%	59.7%	71.0%	73.0%	73.8%	72.2%
R&D Expenses	$28.9B	$39.9B	$38.3B	$42.8B	$36.3B	$34.8B	$33.5B	$42.5B
SG&A Expenses	$27.9B	$30.5B	$35.3B	$31.9B	$31.1B	$30.1B	$31.7B	$30.8B
Operating Expenses	$57.3B	$69.9B	$73.6B	$74.7B	$67.3B	$64.9B	$65.3B	$73.3B
Operating Income	$30.7B	$25.5B	$14.8B	-$7.7B	$23.2B	$29.8B	$38.0B	$12.4B
Operating Margin	26.1%	20.8%	11.0%	-6.8%	18.2%	23.0%	27.1%	10.5%
Interest Expense	$75M	$3.4B	$0	$2.5B	$773M	$1.2B	$408M	$1.1B
Income Before Tax	$33.3B	$21.3B	$17.4B	-$12.7B	$22.6B	$29.5B	$37.2B	$3.3B
Tax Expense	$8.5B	$4.5B	$2.5B	-$6.3B	$5.0B	$7.2B	$8.3B	$2.2B
Net Income	$24.8B	$16.8B	$14.9B	-$6.5B	$17.6B	$22.5B	$28.9B	$818M
Net Margin	21.1%	13.7%	11.1%	-5.8%	13.8%	17.4%	20.6%	0.7%
EPS (Diluted)	$52.75	$35.82	$31.81	$-13.93	$37.58	$47.70	$61.42	$1.72
EBITDA	$35.1B	$29.8B	$24.0B	-$1.5B	$32.7B	$40.1B	$47.2B	$14.0B
Shares Outstanding	470M	470M	470M	470M	468M	472M	470M	477M

4528.T JPX